Payment overview · 2025
General Payments
$383.32
19 reported records · 11 companies
Healthcare provider profile · identity verified
Mark Vinson, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MARTIN, TN · NPI 1699255794
Verified facts
What the public records show
CMS Open Payments records show Mark Vinson, FNP-BC received $383.32 in general payments during 2025 across 19 reported records.
Viatris Specialty LLC accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $68.30 | 17.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.85 | 15.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.62 | 13.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 11.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.02 | 9.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.42 | 6.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.06 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 5.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.72 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.79 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.06 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $338.32 | 18 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.04 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $68.30 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 121 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 854 | 133 |
| Gabapentin | Gabapentin | 416 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 312 | 97 |
| Lisinopril | Lisinopril | 285 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 72 |
| Losartan Potassium | Losartan Potassium | 207 | 59 |
| Furosemide | Furosemide | 198 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 60 |
| Omeprazole | Omeprazole | 187 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 54 |
| Metformin Hcl | Metformin Hcl | 184 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 22 |
| Montelukast Sodium | Montelukast Sodium | 162 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 45 |
| Ozempic | Semaglutide | 156 | 27 |
| Potassium Chloride | Potassium Chloride | 149 | 48 |
| Buspirone Hcl | Buspirone Hcl | 143 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 43 |
| Meloxicam | Meloxicam | 136 | 46 |
| Alprazolam | Alprazolam | 135 | 24 |
| Promethazine Hcl | Promethazine Hcl | 134 | 28 |
| Sertraline Hcl | Sertraline Hcl | 134 | 37 |
| Trazodone Hcl | Trazodone Hcl | 127 | 35 |
| Famotidine | Famotidine | 126 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 18 |
| Farxiga | Dapagliflozin Propanediol | 121 | 25 |
| Simvastatin | Simvastatin | 118 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 34 |
| Pregabalin | Pregabalin | 116 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 32 |
| Prednisone | Prednisone | 102 | 57 |
| Ibuprofen | Ibuprofen | 99 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 33 |
| Cephalexin | Cephalexin | 93 | 78 |
| Carvedilol | Carvedilol | 90 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 23 |
| Jardiance | Empagliflozin | 79 | 25 |
| Clonazepam | Clonazepam | 75 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 13 |
| Atenolol | Atenolol | 69 | 13 |
| Clonidine Hcl | Clonidine Hcl | 69 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 16 |
| Methocarbamol | Methocarbamol | 65 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 20 |
| Vraylar | Cariprazine Hcl | 65 | 12 |
| Eliquis | Apixaban | 63 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 13 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Linzess | Linaclotide | 58 | 17 |
| Mounjaro | Tirzepatide | 58 | 12 |
| Nitroglycerin | Nitroglycerin | 58 | 18 |
| Diazepam | Diazepam | 57 | 12 |
| Topiramate | Topiramate | 56 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 23 |
| Mirtazapine | Mirtazapine | 54 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Aripiprazole | Aripiprazole | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 13 |
| Glimepiride | Glimepiride | 48 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | 13 |
| Allopurinol | Allopurinol | 47 | suppressed |
| Baclofen | Baclofen | 46 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 15 |
| Divalproex Sodium | Divalproex Sodium | 43 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 16 |
| Ondansetron Odt | Ondansetron | 43 | 16 |
| Prazosin Hcl | Prazosin Hcl | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 34 |
| Tramadol Hcl | Tramadol Hcl | 38 | 18 |
| Amoxicillin | Amoxicillin | 37 | 33 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | 12 |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Estradiol | Estradiol | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Nystatin | Nystatin | 24 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | 11 |
| Azelastine Hcl | Azelastine Hcl | 20 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | 16 |
| Mupirocin | Mupirocin | 17 | 17 |
| Nabumetone | Nabumetone | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 11 |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.32 · 19 records | Viatris Specialty LLC | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, YUPELRI, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error